{
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "document": "CDC_Influenza_vaccines",
  "supporting_evidence": [],
  "image_supporting_evidence": [
    {
      "image_filename": "figure_p1_det_0_011.png",
      "explanation": "A slide showing a table comparing four influenza vaccine manufacturing platforms (egg-based, recombinant, MF59-adjuvanted egg-based, and cell-based), with bullet points under each platform detailing features such as production timelines, egg adaptation effects, antigen match, and immune response characteristics. Evidence: Under the Recombinant platform column: \"Broader immune response\" and \"Cross-protection\". The image explicitly lists recombinant technology as providing a broader immune response and cross-protection, which supports the claim."
    }
  ],
  "evidence_summary": {
    "total_text_evidence_found": 0,
    "total_image_evidence_found": 1,
    "total_evidence_found": 1,
    "coverage": "complete",
    "missing_aspects": []
  },
  "metadata": {
    "extraction_stats": {
      "total_verified": 0
    },
    "rejected_count": 0
  }
}